YANG MICHAEL J. 4
4 · Pacira BioSciences, Inc. · Filed Jun 12, 2026
Research Summary
AI-generated summary of this filing
Pacira (PCRX) Director Michael Yang Receives Equity Awards
What Happened
Michael J. Yang, a director of Pacira BioSciences, reported receiving two equity awards on June 10, 2026: 6,405 restricted stock units (RSUs) and a derivative award covering 10,891 shares. Both items were reported at $0.00 (no cash paid). These are grants/awards (not purchases or sales) and were submitted on a Form 4 filed June 12, 2026.
Key Details
- Transaction date: June 10, 2026; Form 4 filed June 12, 2026.
- Price: $0.00 reported for both awards; aggregate reported cash consideration = $0.
- Shares owned after the transaction: not specified in the filing.
- Footnotes: F1 — the 6,405 RSUs vest on June 10, 2027 if the director remains in continuous service; each RSU converts to one share. F2 — the 10,891-share derivative is a stock option that vests and becomes exercisable on June 10, 2027, subject to continuous service.
- Timeliness: Filing appears to be within the typical 2-business-day Form 4 reporting window.
Context
These entries are compensation-related awards that vest in one year; the derivative entry represents a future right to acquire shares (an option) rather than an immediate transfer of stock. No shares were exercised or sold in this filing. Such grants are common for directors and do not by themselves indicate a change in the director’s market view.
Insider Transaction Report
- Award
Common Stock
[F1]2026-06-10+6,405→ 19,798 total - Award
Stock Option (Right to Buy)
[F2]2026-06-10+10,891→ 10,891 totalExercise: $23.42From: 2027-06-10Exp: 2036-06-10→ Common Stock (10,891 underlying)
Footnotes (2)
- [F1]Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
- [F2]The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.